Compare Amphastar Pharmaceuticals Inc (AMPH) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.78 (market cap $868.62M), while 22nd Century Group Inc trades at $4.46 (market cap $1.52M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 571.5× 22nd Century Group Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XXII | |
|---|---|---|
Market Cap | $868.62M | $1.52M |
Sector | Health | Technology |
52-Week High | $30.81 | $801.00 |
52-Week Low | $16.87 | $3.72 |
Enterprise Value | $1.27B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
XXII trades at $4.46, up 2.53% today, with a neutral technical signal and bearish moving averages. The company shows deep losses with a net income margin of -65.76% and negative ROE of -130.19%, though it beat earnings in Q3 2025. Recent news highlights VLN® retail expansion in California and New York, and a reverse stock split on June 12, 2026. Cash flow remains dependent on financing, with operating cash flow negative at -$7.72 million in 2025.
Outlook is speculative; analyst consensus is 75% buy with growth potential from VLN® market expansion, but high execution and regulatory risks persist. Investment hinges on revenue scaling to offset persistent losses, with stock volatility expected near key resistance at $5.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
